Actavis Specialty Brands focuses primarily on the development and commercialization of branded pharmaceuticals within the Urology and Women’s Health therapeutic categories.

Actavis Specialty Brands currently markets more than 40 brand products in the U.S., and is focused growing and expanding its Specialty Brands business globally.

In Canada, in 2012, Actavis launched and currently markets Rapaflo®, Gelnique®, Androderm®, and Oxytrol®, and has deployed a sales force of 24 representatives calling on urologists and primary care physicians to detail these products.

The Company is actively pursuing opportunities in Latin America, and the selective commercialization of a portfolio of products in markets around the world.

To report adverse events and product complaints for Watson, Actavis and Arrow products outside the U.S. please contact the Marketing Authorization Holder for the product. Contact details for Marketing Authorisation Holder are listed in the leaflet or labeling accompanying the product.